PTGS2 and metastatic malignant neoplasm in the lymph nodes: The previous studies have supported our finding that the intense COX-2 immunolabeling was associated with lymph node metastasis, the development of distant metastasis, and a worse prognosis in canine mammary carcinomas [26, 27].